Sygnature Discovery Forms a Strategic Alliance with ApconiX

02 October 2017 – Nottingham and Alderley Park, UK – Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise, has announced it is to work in partnership with ApconiX, experts in non-clinical safety strategies and ion channel screening, to offer a broader range of drug discovery services.

Dr Paul Clewlow, Senior VP, Business Development, recently signed the strategic alliance document with ApconiX which will allow them to add extra value and capabilities to Sygnature’s clients, specifically in the area of toxicology. The alliance will strengthen Sygnature’s integrated drug discovery service offering to accelerate the discovery of new medicines from the lab into development for clients.

ApconiX is a team of world-renowned non-clinical safety experts with over 300 years of drug discovery and development expertise. They provide advice that helps scientists to make better decisions on drug safety, from project initiation through to worldwide marketing approval, guiding you towards scientific and regulatory success.

Based in the BioHub at Alderley Park, Cheshire – part of the BioCity Group where Sygnature Discovery is headquartered – ApconiX delivers high quality, cost-effective pre-clinical safety packages that align with drug discovery projects.

Dr Clewlow of Sygnature Discovery commented:

“Toxicology and functional electrophysiology assessments are essential aspects of the drug discovery and development process to ensure the safety of a potential drug prior to administration in humans.  The specialists at ApconiX are world renowned scientists in non-clinical safety strategies and their skills will be of great benefit to our clients.  The alliance between Sygnature Discovery and ApconiX will be mutually beneficial and together we can offer a more comprehensive integrated approach to any clients’ drug discovery programme.

We are very much looking forward to working with ApconiX and introducing them to our clients.”

Dr Michael Morton, Director and Co-Founder of ApconiX, commented:

“The combination of our expertise in discovery toxicology and ion channel testing, with that of Sygnature’s medicinal chemistry-driven integrated drug discovery services, will help clients to make safer drugs. Our ability to run high-throughput screens for important ion channel targets also compliments Sygnature’s extensive biology capability. This is a hugely exciting partnership!”

 

By | 2018-06-06T14:50:03+00:00 October 3rd, 2017|Press|Comments Off on Sygnature Discovery Forms a Strategic Alliance with ApconiX

About the Author:

Professor Ruth A Roberts, PhD, ATS, FBTS, ERT, FRSB, FRCPath Director and Cofounder, ApconiX, UK and Chair and Director of Drug Discovery, University of Birmingham, UK Ruth is chair of drug discovery at Birmingham University, UK and Cofounder of ApconiX, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Previously, Ruth was Global Head of Regulatory Safety at AstraZeneca and Director of Toxicology for Aventis. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development. With >140 publications in peer reviewed journals, she is focused on reducing attrition attributable to safety and toxicity. A former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT and president elect of the Academy of Toxicological Sciences, Ruth was the recipient of the SOT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009 and the SOT Founders award in 2018 for outstanding leadership in toxicology.